NYSE American To Suspend Trading In Navidea Biopharmaceuticals
Portfolio Pulse from Benzinga Newsdesk
The NYSE American has announced that it will suspend trading in Navidea Biopharmaceuticals (NAVB).
October 05, 2023 | 8:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Trading in Navidea Biopharmaceuticals will be suspended by NYSE American, which could lead to increased volatility in the stock's price.
The suspension of trading in a stock typically leads to increased volatility in its price, as it creates uncertainty among investors. This could potentially lead to a decrease in NAVB's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100